Thermo Fisher Scientific (TMO) Shares Sold by Connable Office Inc.

Connable Office Inc. trimmed its stake in shares of Thermo Fisher Scientific (NYSE:TMO) by 4.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,907 shares of the medical research company’s stock after selling 823 shares during the period. Thermo Fisher Scientific comprises about 0.7% of Connable Office Inc.’s portfolio, making the stock its 23rd largest position. Connable Office Inc.’s holdings in Thermo Fisher Scientific were worth $3,697,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of TMO. Longview Partners Guernsey LTD increased its stake in Thermo Fisher Scientific by 6.8% in the 4th quarter. Longview Partners Guernsey LTD now owns 4,876,890 shares of the medical research company’s stock valued at $926,024,000 after buying an additional 311,977 shares during the last quarter. Geode Capital Management LLC increased its stake in Thermo Fisher Scientific by 4.2% in the 4th quarter. Geode Capital Management LLC now owns 3,917,221 shares of the medical research company’s stock valued at $742,108,000 after buying an additional 158,961 shares during the last quarter. Wells Fargo & Company MN increased its stake in Thermo Fisher Scientific by 0.3% in the 1st quarter. Wells Fargo & Company MN now owns 3,198,908 shares of the medical research company’s stock valued at $660,446,000 after buying an additional 9,820 shares during the last quarter. Clearbridge Investments LLC increased its stake in Thermo Fisher Scientific by 5.3% in the 4th quarter. Clearbridge Investments LLC now owns 2,862,399 shares of the medical research company’s stock valued at $543,512,000 after buying an additional 143,518 shares during the last quarter. Finally, C WorldWide Group Holding A S increased its stake in Thermo Fisher Scientific by 1.9% in the 4th quarter. C WorldWide Group Holding A S now owns 2,277,108 shares of the medical research company’s stock valued at $432,378,000 after buying an additional 43,368 shares during the last quarter. Institutional investors and hedge funds own 86.52% of the company’s stock.

Several equities research analysts have issued reports on TMO shares. Zacks Investment Research lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Thursday, April 5th. Bank of America lifted their price target on shares of Thermo Fisher Scientific from $235.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, February 1st. Morgan Stanley lowered their price target on shares of Thermo Fisher Scientific from $228.00 to $216.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 11th. ValuEngine upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. Finally, Barclays lifted their price target on shares of Thermo Fisher Scientific from $225.00 to $245.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. One analyst has rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $222.21.

Shares of Thermo Fisher Scientific opened at $211.01 on Friday, according to MarketBeat Ratings. Thermo Fisher Scientific has a one year low of $209.10 and a one year high of $211.31. The stock has a market capitalization of $84.12 billion, a PE ratio of 22.23, a PEG ratio of 1.53 and a beta of 1.14. The company has a quick ratio of 0.95, a current ratio of 1.36 and a debt-to-equity ratio of 0.69.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 25th. The medical research company reported $2.50 EPS for the quarter, beating analysts’ consensus estimates of $2.42 by $0.08. Thermo Fisher Scientific had a net margin of 10.24% and a return on equity of 16.09%. The company had revenue of $5.85 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same quarter last year, the firm posted $2.08 EPS. The company’s quarterly revenue was up 22.8% on a year-over-year basis. research analysts forecast that Thermo Fisher Scientific will post 10.9 earnings per share for the current fiscal year.

In other news, CEO Marc N. Casper sold 40,000 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, March 22nd. The shares were sold at an average price of $210.16, for a total value of $8,406,400.00. Following the completion of the transaction, the chief executive officer now owns 334,622 shares of the company’s stock, valued at approximately $70,324,159.52. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Stephen Williamson sold 2,500 shares of Thermo Fisher Scientific stock in a transaction dated Monday, March 5th. The shares were sold at an average price of $204.60, for a total transaction of $511,500.00. The disclosure for this sale can be found here. In the last three months, insiders sold 43,500 shares of company stock valued at $9,129,330. Insiders own 0.49% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply